Big Ideas, Real Impact

Our Vision

To ensure that the future of plastic surgery is shaped by those who practice it. By investing in clinically meaningful technologies, ASPS Ventures safeguards the specialty’s leadership role, improves care for millions of patients and creates sustainable long-term value for investors and the Society.

Why Is ASPS Ventures a Credible GP?

  • Institutional stability with long-term alignment

  • Institutional governance and balance-sheet stability

  • Surgeon-led diligence

  • Long-term alignment

  • Mission-backed platform

  • We invest in breakthrough medtech that improves patient outcomes and strengthens the specialty through safety, efficiency and innovation

  • We connect surgeons, founders, strategic partners and investors to bring clinically validated technologies to market.

  • We measure success through improved surgical outcomes, accelerated technology adoption and strong financial performance.

Our Process

APPLY

Submit your company through our online application for initial consideration.

SCREEN

Our team reviews overall strategic fit, traction, regulatory status and alignment with the ASPS network.

PITCH

Selected companies are invited to present to the ASPS Ventures.

DUE DILIGENCE

Selected companies undergo due diligence, evaluating clinical, commercial, financial and strategic aspects of the company.

INVESTMENT

Approved companies receive investment and strategic support from ASPS Ventures.

What Makes Us Different?

 

  • Our greatest asset – and the core value to co-investors – is the active participation of ASPS Key Opinion Leaders (KOLs).

    • They screen and select companies based on real clinical need.

    • They participate directly in due diligence, product evaluation and early validation.

    • They provide founders with expert guidance on regulatory pathways, clinical trials, surgical workflow integration and adoption dynamics.

    This deep clinical involvement is not available in traditional VC funds, giving ASPS-vetted portfolio companies a materially higher probability of achieving product-market fit, surgeon adoption and strategic exit.

  • Through ASPS’s multi-year partnership with MedTech Innovator, the premier global accelerator for medical devices, ASPS receives early access to a steady stream of technologies pre-screened for relevance to plastic surgery.

    • Hundreds of applications per year

    • ASPS-run clinical screening

    • Exclusive selection of five annual companies for the ASPS Track

    • Historic outperformance of ASPS-selected companies within MTI cohorts

    This pipeline uniquely positions the ASPS Ventures to invest earlier, with more information and with higher confidence in clinical relevance than generalist VCs.

  • The Board of Directors of ASPS Ventures consists of high-profile, widely respected plastic surgeons who bring decades of clinical leadership, research expertise and specialty stewardship.

    Board members are financially incentivized to ensure the success of the funds and maintain a rigorous, mission-aligned investment process. Their involvement enhances credibility with founders, co-investors and strategic acquirers.

  • Medtech startups require early validation, clinical partners and market understanding – precisely what ASPS can uniquely provide.

    • Access to a global network of 12,000 plastic surgeons

    • Clinical trial feasibility and early pilot opportunities

    • Specialty-specific KOL endorsements

    • Real-world user feedback that drives product refinement and regulatory traction

    • Visibility across academic centers, private practices and industry partners

    This level of specialty-specific access materially accelerates commercialization and increases strategic acquisition interest.

  • Plastic and reconstructive surgery sits at the center of several high-growth healthcare markets.

    • Regenerative medicine

    • Robotics and surgical automation

    • AI-driven diagnostics and imaging

    • Wound healing and tissue regeneration

    • Nerve repair and limb salvage

    • Aesthetic devices and digital therapeutics

    These are expansion markets – large, growing and strategically important, yet fragmented and often overlooked by large generalist VCs.